PharmacoEconomics & Outcomes News 784, p27 - 12 Aug 2017 Switching from Turbuhaler to Spiromax cost saving Switching from the Turbuhaler to the DuoResp Spiromax appears to be cost saving in patients with asthma or chronic obstructive pulmonary disease (COPD) requiring treatment with inhaled budesonide/ formoterol (BF), according to findings of a study published in Respiratory Medicine. A model was used to estimate the cost savings and budget impact of switching from Turbuhaler (which is associated with poor inhalation technique) to Spiromax in patients with asthma and COPD, from the perspective of healthcare payers in Germany, Italy, Sweden and the UK over a 3-year time horizon. Two scenarios were considered: switching all patients immediately from Turbuhaler to Spiromax; or switching 4%, 8% and 12% of patients during year 1, 2 and 3, respectively. When all patients were immediately switched from Turbuhaler to Spiromax, estimated cost savings per patient were €60.10 in Germany, €49.67 in Italy, €94.14 in Sweden and €38.20 in the UK. Over the 3-year period, the estimated number of healthcare events avoided per country was 597 754, 151 480, 228 986 and 122 368, respectively, and estimated total cost savings per country were €100.86 million, €19.42 million, €36.65 million and €15.44 million, respectively. Under the second scenario when 4%–12% of patients were progressively switched to Spiromax, estimated savings per patient were €4.81, €3.97, €7.53 and €3.06, respectively, and total cost savings per country were €8.07 million, €1.55 million, €2.93 million and €1.23 million, respectively. "Differences in per patient costs between the countries studied are most likely due to differences in the cost of hospitalisation, as this was the largest contributor to the cost of poor inhalation technique," noted the authors. "Our model suggests that switching ® ® patients from BF Turbuhaler to BF Spiromax could lead to improved inhalation technique, thereby reducing the frequency of unscheduled healthcare events," they concluded. * 2015 euros Lewis A, et al. Budesonide + formoterol delivered via Spiromax(R) for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler(R). Respiratory Medicine 129: 179-188, Aug 2017. Available from: URL: http:// doi.org/10.1016/j.rmed.2017.06.018 803261753 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784
PharmacoEconomics & Outcomes News – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera